文献速递胸部肿瘤

ERBB2突变转移性非小细胞肺癌:靶向治疗的疗效与耐药

ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.
PubMed 文献 · J Thorac Oncol · 2017-02-04

本文报告9例ERBB2突变转移性肺腺癌患者接受ERBB2靶向治疗的结果,其中4例有效,缓解持续时间3至10个月。新发PIK3CA突变和ERBB2拷贝数增加被鉴定为潜在耐药机制。

要点

  • 9例ERBB2突变转移性肺腺癌中4例对靶向治疗有缓解,持续3至10个月。
  • 新发PIK3CA突变与ERBB2拷贝数增加为潜在耐药机制。
  • ERBB2突变肺腺癌患者可对靶向治疗产生缓解,进展时需识别耐药机制。

核心结论

  • ERBB2突变肺腺癌患者可对靶向治疗产生缓解,进展时发现潜在耐药机制。

研究设计与样本

  • 报告9例接受ERBB2靶向治疗的转移性肺腺癌伴ERBB2突变患者的结局。

主要发现

  • 9例中4例对靶向治疗有缓解,缓解持续3至10个月。
  • 发现新发PIK3CA突变和ERBB2拷贝数增加为潜在耐药机制。

关键数值与推荐

  • ERBB2体细胞突变在肺腺癌患者中报告为1%至2%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Erb-b2 receptor tyrosine kinase 2 gene (ERBB2) (also called HER2) has long been recognized as an oncogenic driver in some breast and gastroesophageal cancers in which amplification of this gene confers sensitivity to treatment with Erb-b2 receptor tyrosine kinase 2 (ERBB2)-directed agents. More recently, somatic mutations in ERBB2 have been reported in 1% to 2% of patients with lung adenocarcinoma. Previous case series have suggested clinical tumor responses using anti-ERBB2 small molecules and antibody therapies. METHODS: Here we report the outcomes of nine patients with metastatic lung adenocarcinoma with ERBB2 mutations being treated with ERBB2-targeted therapies. RESULTS: Four of the nine patients had response to targeted therapies, with durations of response ranging from 3 to 10 months. We identified a de novo phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA) mutation and ERBB2 copy number gain as potential resistance mechanisms. CONCLUSIONS: We showed patients with ERBB2-mutated lung adenocarcinoma can respond to targeted therapies, and we identified potential resistance mechanisms upon progression to targeted therapies.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Chuang JC, Stehr H, Liang Y, et al. ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. J Thorac Oncol. 2017. PMID: 28167203. doi:10.1016/j.jtho.2017.01.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。